AbbVie’s blockbuster drug Humira finally loses its 20-year, $200 billion monopoly
U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.
(Image credit: JB Reed/Bloomberg via Getty Images)
